[go: up one dir, main page]

EP2765227A3 - Compositions and methods for identifying autism spectrum disorders - Google Patents

Compositions and methods for identifying autism spectrum disorders Download PDF

Info

Publication number
EP2765227A3
EP2765227A3 EP14000228.8A EP14000228A EP2765227A3 EP 2765227 A3 EP2765227 A3 EP 2765227A3 EP 14000228 A EP14000228 A EP 14000228A EP 2765227 A3 EP2765227 A3 EP 2765227A3
Authority
EP
European Patent Office
Prior art keywords
methods
autism spectrum
compositions
spectrum disorders
identifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14000228.8A
Other languages
German (de)
French (fr)
Other versions
EP2765227A2 (en
Inventor
Valerie Wailin Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
George Washington University
Original Assignee
George Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Washington University filed Critical George Washington University
Publication of EP2765227A2 publication Critical patent/EP2765227A2/en
Publication of EP2765227A3 publication Critical patent/EP2765227A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides methods of identifying DNA methylation profiles for neurological and psychiatric conditions including autism spectrum disorders, methods of treating such conditions, and methods of identifying therapeutics for the treatment of such neurological and psychiatric conditions.
EP14000228.8A 2010-04-06 2011-04-06 Compositions and methods for identifying autism spectrum disorders Withdrawn EP2765227A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32117210P 2010-04-06 2010-04-06
EP11766672.7A EP2558622A4 (en) 2010-04-06 2011-04-06 COMPOSITIONS AND METHODS FOR IDENTIFYING AUTISM SPECTRUM DISORDERS

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP11766672.7A Division EP2558622A4 (en) 2010-04-06 2011-04-06 COMPOSITIONS AND METHODS FOR IDENTIFYING AUTISM SPECTRUM DISORDERS

Publications (2)

Publication Number Publication Date
EP2765227A2 EP2765227A2 (en) 2014-08-13
EP2765227A3 true EP2765227A3 (en) 2014-12-10

Family

ID=44763268

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11766672.7A Withdrawn EP2558622A4 (en) 2010-04-06 2011-04-06 COMPOSITIONS AND METHODS FOR IDENTIFYING AUTISM SPECTRUM DISORDERS
EP14000228.8A Withdrawn EP2765227A3 (en) 2010-04-06 2011-04-06 Compositions and methods for identifying autism spectrum disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11766672.7A Withdrawn EP2558622A4 (en) 2010-04-06 2011-04-06 COMPOSITIONS AND METHODS FOR IDENTIFYING AUTISM SPECTRUM DISORDERS

Country Status (3)

Country Link
US (1) US20140187430A1 (en)
EP (2) EP2558622A4 (en)
WO (1) WO2011127194A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274767A1 (en) * 2013-01-23 2014-09-18 The Johns Hopkins University Dna methylation markers for metastatic prostate cancer
US10842807B2 (en) 2016-06-13 2020-11-24 Washington University Methods of treating neurodegenerative disorders comprising DNA methyltransferase inhibitors
CN107944222B (en) * 2016-10-13 2020-04-14 中南大学 A method for detecting the occurrence time of cases using the correlation between DNA methylation levels in human peripheral blood and biological rhythms
WO2018107294A1 (en) * 2016-12-15 2018-06-21 The Hospital For Sick Children Dna methylation markers for neuropsychiatric disorders and methods, uses and kits thereof
AU2018275252A1 (en) * 2017-06-01 2019-12-19 Genome Profiling, Llc Identification of epigenetic signatures indicating cerebral palsy
JP7466927B2 (en) * 2018-08-10 2024-04-15 ニューヨーク ユニバーシティ Use of IGF-2 receptor agonist ligands to treat angelman syndrome and autism
KR20210075069A (en) 2018-08-10 2021-06-22 뉴욕 유니버시티 Use of mannose 6 phosphate and variants thereof for improving memory and reducing memory impairment
CN108977461B (en) * 2018-08-21 2021-09-10 中国科学院昆明植物研究所 Application of protein encoded by pPMB1 gene or pPMB1 gene in improving dehydration resistance of plants
US20210180130A1 (en) * 2019-12-13 2021-06-17 Seawire Consultoria e Comercio LDA Detection and treatment of autism spectrum disorders
CN113122631A (en) * 2020-01-14 2021-07-16 上海鹍远生物技术有限公司 Reagent for detecting DNA methylation and application
WO2022020824A2 (en) * 2020-07-22 2022-01-27 Washington State University Methods of identifying autism spectrum disorder
US20250146051A1 (en) * 2022-02-28 2025-05-08 The Johns Hopkins University Methods for identifying risk of autism
WO2024184854A1 (en) * 2023-03-07 2024-09-12 Pomorski Uniwersytet Medyczny W Szczecinie Methods, systems and assosiated computer program products for discriminating type of biological sample of an organism using epigenetic modification information

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029009A1 (en) * 2008-07-28 2010-02-04 Greenwood Genetic Center, Inc. Methods for Determining Dysregulation of Methylation of Brain Expressed Genes on the X Chromosome to Diagnose Autism Spectrum Disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5262300A (en) 1988-11-30 1993-11-16 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0483249B1 (en) 1989-07-18 2003-04-23 OSI Pharmaceuticals, Inc. Method of transcriptionally modulating gene expression and of discovering chemicals capable of functioning as gene expression modulators
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5453362A (en) 1992-12-04 1995-09-26 Tularik Inc. Eukaryotic transcription protein; host cell factor
US5534410A (en) 1993-01-28 1996-07-09 The Regents Of The University Of California TATA-binding protein associated factors drug screens
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5563036A (en) 1994-04-29 1996-10-08 Tularik, Inc. Transcription factor-DNA binding assay
US5612455A (en) 1994-07-05 1997-03-18 Tularik, Inc. Nuclear factors and binding assay
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
JP2000501290A (en) 1995-11-30 2000-02-08 リサーチ ディベロップメント ファンデーション Screening assays for compounds that stimulate somatostatin and insulin production
US5710025A (en) 1996-10-02 1998-01-20 The Regents Of The University Of California Cell-type specific transcription factor
US6028189A (en) 1997-03-20 2000-02-22 University Of Washington Solvent for oligonucleotide synthesis and methods of use
US7013221B1 (en) 1999-07-16 2006-03-14 Rosetta Inpharmatics Llc Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
WO2006034573A1 (en) * 2004-09-27 2006-04-06 Med Biogene Inc. Hematological cancer profiling system
EP2395101B1 (en) * 2005-05-02 2013-11-13 University of Southern California DNA methylation markers associated with the CpG island methylator phenotype (cimp) in human colorectal cancer
WO2008070144A2 (en) * 2006-12-06 2008-06-12 Duke University Imprinted genes and disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029009A1 (en) * 2008-07-28 2010-02-04 Greenwood Genetic Center, Inc. Methods for Determining Dysregulation of Methylation of Brain Expressed Genes on the X Chromosome to Diagnose Autism Spectrum Disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. NGUYEN ET AL: "Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain", THE FASEB JOURNAL, vol. 24, no. 8, 7 April 2010 (2010-04-07), pages 3036 - 3051, XP055126230, ISSN: 0892-6638, DOI: 10.1096/fj.10-154484 *
VALERIE W. HU: "From Genes to Environment: Using Integrative Genomics to Build a "Systems-Level" Understanding of Autism Spectrum Disorders", CHILD DEVELOPMENT, vol. 84, no. 1, 12 January 2013 (2013-01-12), pages 89 - 103, XP055126241, ISSN: 0009-3920, DOI: 10.1111/j.1467-8624.2012.01759.x *

Also Published As

Publication number Publication date
EP2765227A2 (en) 2014-08-13
EP2558622A4 (en) 2013-07-24
EP2558622A1 (en) 2013-02-20
US20140187430A1 (en) 2014-07-03
WO2011127194A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
EP2765227A3 (en) Compositions and methods for identifying autism spectrum disorders
WO2013120022A3 (en) Treatment of hypoglycemia
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
MY165728A (en) Selective glycosidase inhibitors and uses thereof
EP4324527A3 (en) Formulations of enzalutamide
IN2012DN03883A (en)
WO2010056982A3 (en) Compositions and methods for identifying autism spectrum disorders
MY157341A (en) Methods and compositions for treating lung cancer
IL219160A0 (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
WO2009120810A3 (en) Neurodegenerative disorders
WO2009158719A3 (en) Methods and compositions for treating disorders
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
MX2010010303A (en) NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801.
WO2011047091A9 (en) Methods for treating traumatic brain injury
WO2010141956A3 (en) Methods and compositions for the treatment of cancer
WO2012017321A3 (en) Treatment for dyslipidemia
WO2010102154A3 (en) Biaryl oxyacetic acid compounds
WO2010037095A3 (en) Agents and methods for the treatment of cancer
WO2012068332A9 (en) Methods for treating early stage or mild neurological disorders
WO2011029639A3 (en) Compounds and methods for treating neoplasia
WO2011028890A3 (en) Compositions and methods for treatment of neuropathic pain
WO2011062762A3 (en) Angiogenin and variants thereof for treatment of neurodegenerative diseases
WO2012024670A3 (en) Composition and methods for treating glioblastoma
MX2011010046A (en) Diaminopteridine derivatives.
PL2201950T3 (en) Compounds and methods for treating autism spectrum disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140122

AC Divisional application: reference to earlier application

Ref document number: 2558622

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101ALI20141031BHEP

Ipc: C40B 30/04 20060101AFI20141031BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150611